CLC number:
On-line Access: 2021-01-15
Received: 2020-05-08
Revision Accepted: 2020-08-10
Crosschecked: 2020-12-10
Cited: 0
Clicked: 3799
Lily YU, Xiuhua LIU, Xiaochun YU. ADP-ribosylhydrolases: from DNA damage repair to COVID-19[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2000319 @article{title="ADP-ribosylhydrolases: from DNA damage repair to COVID-19", %0 Journal Article TY - JOUR
ADP-核糖基水解酶:从DNA损伤修复到2019新型冠状病毒肺炎关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]AhelD, Ho艡ej拧铆Z, WiechensN, et al., 2009. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science, 325(5945):1240-1243. [2]Am茅JC, SpenlehauerC, de MurciaG, 2004. The PARP superfamily. BioEssays, 26(8):882-893. [3]Am茅JC, FouquerelE, GauthierLR, et al., 2009. Radiation-induced mitotic catastrophe in PARG-deficient cells. J Cell Sci, 122(Pt 12):1990-2002. [4]AudehMW, CarmichaelJ, PensonRT, et al., 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 376(9737):245-251. [5]BarkauskaiteE, BrassingtonA, TanES, et al., 2013. Visualization of poly(ADP-ribose) bound to PARG reveals inherent balance between exo- and endo-glycohydrolase activities. Nat Commun, 4:2164. [6]BarkauskaiteE, JankeviciusG, AhelI, 2015. Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation. Mol Cell, 58(6):935-946. [7]BenekeS, DiefenbachJ, B眉rkleA, 2004. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer, 111(6):813-818. [8]BryantHE, SchultzN, ThomasHD, et al., 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035):913-917. [9]B眉tepageM, EckeiL, VerheugdP, et al., 2015. Intracellular mono-ADP-ribosylation in signaling and disease. Cells, 4(4):569-595. [10]B眉tepageM, PreisingerC, von KriegsheimA, et al., 2018. Nucleolar-nucleoplasmic shuttling of TARG1 and its control by DNA damage-induced poly-ADP-ribosylation and by nucleolar transcription. Sci Rep, 8:6748. [11]ChenDW, VollmarM, RossiMN, et al., 2011. Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases. J Biol Chem, 286(15):13261-13271. [12]ChenSH, YuXC, 2019. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies. Sci Adv, 5(4):eaav4340. [13]DaughertyMD, YoungJM, KernsJA, et al., 2014. Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts. PLoS Genet, 10(5):e1004403. [14]EgloffMP, MaletH, PuticsA, et al., 2006. Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains. J Virol, 80(17):8493-8502. [15]FauzeeNJS, PanJ, WangYL, 2010. PARP and PARG inhibitors鈥攏ew therapeutic targets in cancer treatment. Pathol Oncol Res, 16(4):469-478. [16]FehrAR, JankeviciusG, AhelI, et al., 2018. Viral macrodomains: unique mediators of viral replication and pathogenesis. Trends Microbiol, 26(7):598-610. [17]FeijsKLH, ForstAH, VerheugdP, et al., 2013. Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation. Nat Rev Mol Cell Biol, 14(7):443-451. [18]FeijsKLH, CooperCDO, 沤ajaR, 2020. The controversial roles of ADP-ribosyl hydrolases MACROD1, MACROD2 and TARG1 in carcinogenesis. Cancers (Basel), 12(3):604. [19]FisherAEO, HocheggerH, TakedaS, et al., 2007. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol Cell Biol, 27(15):5597-5605. [20]GarufiG, PalazzoA, ParisI, et al., 2020. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors. Expert Opin Pharmacother, 21(6):687-699. [21]GogolaE, DuarteAA, de RuiterJR, et al., 2019. Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell, 35(6):950-952. [22]GoliaB, MoellerGK, JankeviciusG, et al., 2017. ATM induces MacroD2 nuclear export upon DNA damage. Nucleic Acids Res, 45(1):244-254. [23]GorbalenyaAE, EnjuanesL, ZiebuhrJ, et al., 2006. Nidovirales: evolving the largest RNA virus genome. Virus Res, 117(1):17-37. [24]GrundyGJ, RultenSL, ZengZH, et al., 2013. APLF promotes the assembly and activity of non-homologous end joining protein complexes. EMBO J, 32(1):112-125. [25]HasslerM, JankeviciusG, LadurnerAG, 2011. PARG: a macrodomain in disguise. Structure, 19(10):1351-1353. [26]HoulJH, YeZ, BroseyCA, et al., 2019. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nat Commun, 10:5654. [27]JankeviciusG, HasslerM, GoliaB, et al., 2013. A family of macrodomain proteins reverses cellular mono-ADP-ribosylation. Nat Struct Mol Biol, 20(4):508-514. [28]JankeviciusG, ArizaA, AhelM, et al., 2016. The toxin-antitoxin system DarTG catalyzes reversible ADP-ribosylation of DNA. Mol Cell, 64(6):1109-1116. [29]KassabMA, YuXC, 2019. The role of dePARylation in DNA damage repair and cancer suppression. DNA Repair (Amst), 76:20-29 [30]KassabMA, YuLL, YuXC, 2020. Targeting dePARylation for cancer therapy. Cell Biosci, 10:7. [31]KaufmannT, GrishkovskayaI, PolyanskyAA, et al., 2017. A novel non-canonical PIP-box mediates PARG interaction with PCNA. Nucleic Acids Res, 45(16):9741-9759. [32]KleineH, PorebaE, LesniewiczK, et al., 2008. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell, 32(1):57-69. [33]KowieskiTM, LeeS, DenuJM, 2008. Acetylation-dependent ADP-ribosylation by Trypanosoma brucei Sir2. J Biol Chem, 283(9):5317-5326. [34]KozlowskiM, CorujoD, HothornM, et al., 2018. MacroH2A histone variants limit chromatin plasticity through two distinct mechanisms. EMBO Rep, 19(10):e44445. [35]KrietschJ, RouleauM, 脡Pic, et al., 2013. Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Mol Aspects Med, 34(6):1066-1087. [36]KustatscherG, HothornM, PugieuxC, et al., 2005. Splicing regulates NAD metabolite binding to histone macroH2A. Nat Struct Mol Biol, 12(7):624-625. [37]LambrechtMJ, BrichacekM, BarkauskaiteE, et al., 2015. Synthesis of dimeric ADP-ribose and its structure with human poly(ADP-ribose) glycohydrolase. J Am Chem Soc, 137(10):3558-3564. [38]LaStarzaMW, LemmJA, RiceCM, 1994. Genetic analysis of the nsP3 region of sindbis virus: evidence for roles in minus-strand and subgenomic RNA synthesis. J Virol, 68(9):5781-5791. [39]LeungAKL, McPhersonRL, GriffinDE, 2018. Macrodomain ADP-ribosylhydrolase and the pathogenesis of infectious diseases. PLoS Pathog, 14(3):e1006864. [40]LiM, YuX, 2015. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene, 34(26):3349-3356. [41]LiuC, VyasA, KassabMA, et al., 2017. The role of poly ADP-ribosylation in the first wave of DNA damage response. Nucleic Acids Res, 45(14):8129-8141. [42]MaletH, DalleK, Br茅mondN, et al., 2006. Expression, purification and crystallization of the SARS-CoV macro domain. Acta Cryst Sect F Struct Biol Cryst Commun, 62(Pt 4):405-408. [43]MaletH, CoutardB, JamalS, et al., 2009. The crystal structures of Chikungunya and Venezuelan equine encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. J Virol, 83(13):6534-6545. [44]Marjanovi膰MP, Hurtado-Bag猫sS, LassiM, et al., 2017. MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD+ consumption. Nat Struct Mol Biol, 24(11):902-910. [45]MichelsJ, VitaleI, SaparbaevM, et al., 2014. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene, 33(30):3894-3907. [46]MinW, CortesU, HercegZ, et al., 2010. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Carcinogenesis, 31(12):2058-2065. [47]MunnurD, AhelI, 2017. Reversible mono-ADP-ribosylation of DNA breaks. FEBS J, 284(23):4002-4016. [48]MunnurD, BartlettE, Mikol膷evi膰P, et al., 2019. Reversible ADP-ribosylation of RNA. Nucleic Acids Res, 47(11):5658-5669. [49]NanYC, YuY, MaZX, et al., 2014. Hepatitis E virus inhibits type I interferon induction by ORF1 products. J Virol, 88(20):11924-11932. [50]NeuvonenM, AholaT, 2009. Differential activities of cellular and viral macro domain proteins in binding of ADP-ribose metabolites. J Mol Biol, 385(1):212-225. [51]PatelCN, KohDW, JacobsonMK, et al., 2005. Identification of three critical acidic residues of poly(ADP-ribose) glycohydrolase involved in catalysis: determining the PARG catalytic domain. Biochem J, 388(Pt 2):493-500. [52]PerinaD, Miko膷A, AhelJ, et al., 2014. Distribution of protein poly(ADP-ribosyl)ation systems across all domains of life. DNA Repair (Amst), 23:4-16. [53]PillayN, TigheA, NelsonL, et al., 2019. DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(ADP-ribose) glycohydrolase inhibitors. Cancer Cell, 35(3):519-533.e8. [54]PoltronieriP, MiwaM, 2016. Editorial (thematic issue: overview on ADP ribosylation and PARP superfamily of proteins). Curr Protein Pept Sci, 17(7):630-632. [55]PowellSN, KachnicLA, 2003. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene, 22(37):5784-5791. [56]RackJGM, MorraR, BarkauskaiteE, et al., 2015. Identification of a class of protein ADP-ribosylating sirtuins in microbial pathogens. Mol Cell, 59(2):309-320. [57]RackJGM, PerinaD, AhelI, 2016. Macrodomains: structure, function, evolution, and catalytic activities. Annu Rev Biochem, 85:431-454. [58]RackJGM, PalazzoL, AhelI, 2020. (ADP-ribosyl)hydrolases: structure, function, and biology. Genes Dev, 34(5-6):263-284. [59]RosenthalF, FeijsKLH, FrugierE, et al., 2013. Macrodomain-containing proteins are new mono-ADP-ribosylhydrolases. Nat Struct Mol Biol, 20(4):502-507. [60]RuizPD, HamiltonGA, ParkJW, et al., 2019. MacroH2A1 regulation of poly(ADP-ribose) synthesis and stability prevents necrosis and promotes DNA repair. Mol Cell Biol, 40(1):e00230-19. [61]SharifiR, MorraR, AppelCD, et al., 2013. Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease. EMBO J, 32(9):1225-1237. [62]ShiraiH, PoetschAR, GunjiA, et al., 2013. PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathways. Cell Death Dis, 4:e656. [63]ShullNP, SpinelliSL, PhizickyEM, 2005. A highly specific phosphatase that acts on ADP-ribose 1"-phosphate, a metabolite of tRNA splicing in Saccharomyces cerevisiae. Nucleic Acids Res, 33(2):650-660. [64]SimonNC, AktoriesK, BarbieriJT, 2014. Novel bacterial ADP-ribosylating toxins: structure and function. Nat Rev Microbiol, 12(9):599-611. [65]SladeD, 2020. PARP and PARG inhibitors in cancer treatment. Genes Dev, 34(5-6):360-394. [66]TalhaouiI, LebedevaNA, ZarkovicG, et al., 2016. Poly(ADP-ribose) polymerases covalently modify strand break termini in DNA fragments in vitro. Nucleic Acids Res, 44(19):9279-9295. [67]TuckerJA, BennettN, BrassingtonC, et al., 2012. Structures of the human poly(ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives. PLoS ONE, 7(12):e50889. [68]VyasS, MaticI, UchimaL, et al., 2014. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun, 5:4426. [69]WeiHT, YuXC, 2016. Functions of PARylation in DNA damage repair pathways. Genomics Proteomics Bioinformatics, 14(3):131-139. [70]YangCS, JividenK, SpencerA, et al., 2017. Ubiquitin modification by the E3 ligase/ADP-ribosyltransferase Dtx3L/Parp9. Mol Cell, 66(4):503-516.e5. [71]YangXY, MaYL, LiYM, et al., 2020. Molecular basis for the MacroD1-mediated hydrolysis of ADP-ribosylation. DNA Repair (Amst), 94:102899. [72]YuM, SchreekS, CerniC, et al., 2005. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene, 24(12):1982-1993. Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>